Plasminogen Activators and Gastrointestinal Neoplasms

References

• Blasi F, Riccio A, Sebastio G. Human plasminogen activators. Genes and proteins structure. Horizons in biochemistry and biophysics. Vol. 8. Human genes and disease, E Oua-Gliariello, F Palmieri, Blasi. John Wiley & Sons, New York 1986; 377–414
   Google Scholar
• Pannell R, Gurewich V. Activation of plasminogen by single-chain urokinase or by two-chain urokinase–a demonstration that single-chain urokinase has a low catalytic activity (pro-urokinase). Blood 1987; 69: 22–26
   PubMedGoogle Scholar
• Andreasen P A, Nielsen L S, Kristensen P, Gron-dahl-Hansen J, Skriver L, Danø K. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J Biol Chem 1986; 261: 7644–7651
   PubMedGoogle Scholar
• Sprengers E D, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381–387
   PubMed Web of Science ®Google Scholar
• Granelli-Piperno A, Reich E. A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med 1978; 148: 223–234
   PubMed Web of Science ®Google Scholar
• Vetterlein D, Young P L, Bell T E, Robin R. Immunological characterization of multiple molecular weight forms of human cell plasminogen activator. J Biol Chem 1979; 254: 575–578
   PubMedGoogle Scholar
• Verheijen J H, Mullaart E, Chang G TC, Kluft C, Wijngaards G. A simple, sensitive spectrophoto-metric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemostas 1982; 48: 266–269
   PubMed Web of Science ®Google Scholar
• Stephens R, Leung K C, Pollanen J, Salonen E M, Vaheri A. Microplate immunocapture assay for plasminogen activators and their specific inhibitors. J Immunol Methods 1987; 105: 245–251
   PubMedGoogle Scholar
• Schieef R R, Wagner N V, Loskutoff D J. Detection of both type 1 and type 2 plasminogen activator inhibitors in human cells. J Cell Physiol 1988; 134: 269–274
   PubMedGoogle Scholar
• Danø K, Andreasen P A, Grøndahl-Hansen J, Kristensen P, Nielsen L S, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985; 44: 139–166
   PubMed Web of Science ®Google Scholar
• Markus G. Plasminogen activators in malignant growth. Progress in fibrinolysis, J F Davidson, F Bachman, C A Bouvier, R O Kruithof. Churchill Livingstone, London 1984; Vol. VI: 587–604
   Google Scholar
• Unkeless J C, Tobia A, Ossowski L, Quigley J P, Rifkin B, Reich E. An enzymatic function associated with transformation of fibroblasts by oncogenic viruses. I. Chick embryo fibroblasts cultures transformed by avian RNA tumour viruses. J Exp Med 1973; 137: 85–111
   PubMed Web of Science ®Google Scholar
• Wigler M, Weinstein I B. Tumourpromotorinduces plasminogen activator. Nature 1976; 259: 232–233
   PubMed Web of Science ®Google Scholar
• Rifkin D B, Loeb J N, Moore G, Rerdi E. Properties of plasminogen activators formed by neoplastic human cell cultures. J Exp Med 1974; 139: 1317–1328
   PubMed Web of Science ®Google Scholar
• Wilson E L, Dowle E. Secretion of plasminogen activator by normal, reactive and neoplastic human tissues cultured in vitro. Int J Cancer 1978; 23: 390–399
   Google Scholar
• Friedman E A. Differential response of prema-lignant epithelial cell classes to phorbol ester tumour promotors and to deoxycholic acid. Cancer Res 1981; 41: 4588–4599
   PubMed Web of Science ®Google Scholar
• Friedman E A, Urmacher C, Winawer D. A model for human colon carcinoma evolution based on the differential response of cultured preneoplastic, pre-malignant and malignant cells to 12–0-tetradecanoylphorbol-13-acetate. Cancer Res 1984; 44: 1568–1578
   PubMed Web of Science ®Google Scholar
• Cliffton E E, Grossi C E. Fibrinolytic activity of human tumours as measured by the fibrin plate method. Cancer 1955; 8: 1146–1154
   PubMed Web of Science ®Google Scholar
• Evers J L, Patel J, Madeja J M, et al. Plasminogen activator activity and composition in human breast cancer. Cancer Res 1982; 42: 219–226
   PubMed Web of Science ®Google Scholar
• Camiolo S M, Markus G, Evers J L, et al. Plasminogen activator content of neoplastic and benign human prostate tissues; fibrin augmentation of an activator activity. Int J Cancer 1981; 27: 191–198
   PubMedGoogle Scholar
• Markus G, Takita H, Camiolo S M, Corasanti J G, Evers J L, Hobika G H. Content and characterization of plasminogen activators in human lung tumours and normal lung tissue. Cancer Res 1980; 40: 841–848
   PubMed Web of Science ®Google Scholar
• Tissot J D, Hauert J, Bachmann. Characterization of plasminogen activators from normal human breast and colon and from breast and colon carcinomas. Int J Cancer 1984; 34: 295–302
   PubMed Web of Science ®Google Scholar
• Szczepanski M, Lucer C, Zawadzki J, Tolloczko T. Procoagulant and fibrinolytic activities of gastric and colorectal cancer. Int J Cancer 1982; 30: 329–333
   PubMedGoogle Scholar
• Franklin J D, Gervin A S, Bowers D G, Lynch J B. Fibrinolytic activity in human neoplasms. Plast Reconstr Surg 1978; 61: 241–249
   PubMedGoogle Scholar
• Corasanti J G, Celik C, Camiolo S M, et al. Plasminogen activator content of human colon tumours and normal mucosa: separation of enzymes and partial purification. J Natl Cancer Inst 1980; 65: 345–352
   PubMedGoogle Scholar
• Gelister J SK, Mahmoud M, Lewin M R, Gaffney P J, Boulos P B. Plasminogen activators in human colorectal neoplasia. Br Med J 1986; 293: 728–731
   PubMedGoogle Scholar
• de Bruin P AF, Verspaget H W, Griffioen G, Nap M, Verheijen J H, Lamers C BHW. Plasminogen activator activity and composition in human colorectal carcinomas. Fibrinolysis 1987; 1: 57–62
   Google Scholar
• Markus G, Camiolo S M, Kohga S, Madeja J M, Mittelman A. Plasminogen activator secretion of human tumours in short-term organ culture, including a comparison of primary and metastatic colon tumours. Cancer Res 1983; 43: 5517–5525
   PubMed Web of Science ®Google Scholar
• Harvey S R, Lawrence D D, Madeja J M, Abbey S J, Markus G. Secretion of plasminogen activators by human colorectal and gastric tumor explants. Clin Expl Metastasis 1988; 6: 431–450
   PubMed Web of Science ®Google Scholar
• Kirchheimer J C, Huber K, Wagner O, Binder B R. Pattern of fibrinolytic parameters in patients with gastrointestinal carcinomas. Br J Haematol 1987; 66: 85–89
   PubMed Web of Science ®Google Scholar
• Nishino N, Aoki K, Tokura Y, Sakaguchi S, Takada Y, Takada A. The urokinase type of plasminogen activator in cancer of digestive tracts. Thromb Res 1988; 50: 527–535
   PubMed Web of Science ®Google Scholar
• de Bruin P AF, Griffioen G, Verspaget H W, et al. Plasminogen activator profiles in neoplastic tissues of the human colon. Cancer Res 1988; 48: 4520–4524
   PubMed Web of Science ®Google Scholar
• Saksela O, Rifkin D B. Cell-associated plasminogen activation: regulation and physiological functions. Ann Rev Cell Biol 1988; 4: 93–126
   PubMedGoogle Scholar
• de Bruin P AF, Griffioen G, Verspaget H W, Verheijen J H, Lamers C BHW. Plasminogen activators and tumour development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas. Cancer Res 1987; 47: 4654–4657
   PubMedGoogle Scholar
• Sim P S, Stephens R W, Fayle D RH, Doe W F. Urok-inase-type plasminogen activator in colorectal carcinomas and adenomatous polyps: quantitative expression of active and proenzyme. Int J Cancer 1988; 42: 483–488
   PubMed Web of Science ®Google Scholar
• de Bruin P AF. Plasminogen activators in (pre)malignant conditions of the human colon. ICG Printing, Dordrecht 1988; 76–88
   Google Scholar
• Muto T, Bussey H JR, Morson B C. The evolution of cancer of the colon and rectum. Cancer 1975; 36: 2251–2270
   PubMed Web of Science ®Google Scholar
• Verspaget H W, de Bruin P AF, Verheijen J H, Grif-Floen G, Lamers C BHW. Plasminogen activators in human colorectal neoplasia. Br Med J 1986; 293: 1056
   Google Scholar
• Suzumiya J, Hasui Y, Kohga S, Sumiyoshi A, Hash-Ida S, Ishikawa E. Comparative study of plasminogen activator antigens in colonic carcinomas and adenomas. Int J Cancer 1988; 42: 627–632
   PubMedGoogle Scholar
• Gyde S N, Prior P, McCartney J C, Thompson H, Waterhouse J AH, Allan R N. Malignancy in Crohn's disease. Gut 1980; 21: 1024–1029
   PubMed Web of Science ®Google Scholar
• Greenstein A J, Sachar D B, Smith H, Janowitz H D, Aufses A H. A comparison of cancer risk in Crohn's disease and ulcerative colitis. Cancer 1981; 48: 2742–2745
   PubMed Web of Science ®Google Scholar
• Hammarberg C, Slezak P, Tribukait B. Early detection of malignancy in ulcerative colitis: a flow-cyto-metric DNA study. Cancer 1984; 53: 291–295
   PubMedGoogle Scholar
• Kwaan H C, Cocco A, Mendeloff I, Astrup T. Fibrinolytic activity in the normal and inflamed rectal mucosa. Scand J Gastroenterol 1969; 4: 441–445
   PubMed Web of Science ®Google Scholar
• Swan C HJ, Alexander Williams J, Cooke W T. Fibrinolysis in colonic disease. Gut 1970; 11: 588–591
   PubMedGoogle Scholar
• Salter R F, Read A E. Epsilon-aminocaproic acid therapy in ulcerative colitis. Gut 1970; 11: 585–587
   PubMedGoogle Scholar
• Hollanders P, Thompson J H, Schofield P F. Tranex-amic acid therapy in ulcerative colitis. Postgrad Med J 1982; 58: 87–91
   PubMed Web of Science ®Google Scholar
• Elliott R, Stephens R W, Doe W F. Expression of urokinase-type plasminogen activator in the mucosal lesions of inflammatory bowel disease. J Gastroenterol Hepatol 1987; 2: 517–523
   Google Scholar
• de Bruin P AF, Crama-Bohbouth G, Verspaget H W, et al. Plasminogen activators in the intestine of patients with inflammatory bowel disease. Thromb Haemostas 1988; 60: 262–266
   PubMedGoogle Scholar
• de Jong E, Porte R J, Knot E AR, Verheijen J H, Dees J. Disturbed fibrinolysis in patients with inflammatory bowel disease. A study in blood plasma, colon mucosa, and faeces. Gut 1989; 30: 188–194
   PubMed Web of Science ®Google Scholar
• Saksela O. Plasminogen activation and regulation of pericellular proteolysis. Biochim Biophys Acta 1985; 823: 35–65
   PubMed Web of Science ®Google Scholar
• Peterson H. Fibrinolysis and antifibrinolytic drugs in the growth and spread of tumours. Cancer Treat Rev 1977; 4: 213–217
   PubMedGoogle Scholar
• Markus G. The role of hemostasis and fibrinolysis in the metastatic spread of cancer. Semin Thromb Hemostas 1984; 10: 61–70
   PubMedGoogle Scholar
• Markus G. The relevance of plasminogen activators to neoplastic growth. A review of recent literature. Enzyme 1988; 40: 158–172
   PubMedGoogle Scholar
• Ossowski L, Reich E. Antibodies to plasminogen activator inhibit tumour metastasis. Cell 1983; 35: 611–619
   PubMed Web of Science ®Google Scholar
• Ossowski L. Plasminogen activator dependent pathways in the dissimination of human tumor cells in the chick embryo. Cell 1988; 52: 321–328
   PubMedGoogle Scholar
• Cajot J F, Sordat B, Bachmann F. Human primary colon carcinomas xenografted into nude mice. II. Modulation of tumor plasminogen activator activity by the host tissue environment. JNCI 1986; 77: 1099–1105
   PubMedGoogle Scholar
• Boyd D, Florent G, Kim P, Brattain M. Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines. Cancer Res 1988; 48: 3112–3116
   PubMed Web of Science ®Google Scholar
• Kirchheimer J C, Wojta J, Hienert G, et al. Effect of urokinase on the proliferation of primary cultures of human prostatic cells. Thromb Res 1987; 48: 291–298
   PubMedGoogle Scholar
• Kirchheimer J C, Wojta J, Christ G, Binder B R. Proliferation of a human epidermal tumor cell line stimulated by urokinase. FASEB J 1987; 1: 125–128
   PubMed Web of Science ®Google Scholar